Marseilles, France, March 23, 2011 -- Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that it will participate to the following analyst and investor conferences in the coming weeks:
- Benelux Midcap Event in Brussels, Belgium, on March 31 & April 1, 2011
- Paris Smallcap Event in Paris, France, on April 26 & 27, 2011
Innate Pharma is committed to meet on a regular basis with the financial community.
Investors can also find updated information on the company’s website (www.innate-
pharma.com) and contact the investor relations team by writing to investors@innate-
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy
drugs for cancer and inflammatory diseases.
The Company specializes in the development of new monoclonal antibodies targeting
regulation pathways of innate immunity cells. Its most advanced drug-candidate is IPH 2101,
an anti-KIR monoclonal antibody potentiating NK cells activation currently in Phase II clinical
trials in hematologic cancers. Two of its antibody programs in chronic inflammation are out-
licensed to Novo Nordisk A/S.
Innate Pharma’s key expertise is in immunopharmacology and antibody technology. The
Company has implemented in-house a large panel of molecular and cellular assays and in vivo
models for assessing the pharmacodynamics and pharmacotoxicology of drug candidates. In
addition, Innate Pharma has access to a very large set of unique research tools in cellular
immunology through its worldwide network of scientific collaborations.
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in
Marseilles, France, and had 86 employees as at December 31, 2010.
Learn more about Innate Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
This press release contains certain forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these forward-looking statements are subject
to numerous risks and uncertainties, which could cause actual results to differ materially from
those anticipated. For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from those contained in
the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of
the Document de Reference prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma’s website.
This press release and the information contained herein do not constitute an offer to sell or a
solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Innate Pharma Alize Public Relations
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87
Alize Public Relations
Phone: +33 (0)1 41 22 07 31
Mobile: +33 (0)6 64 18 99 59